INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 C12N5/10 A61P3/00

A01K67/027

G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 . A61K C12N C12Q G01N A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ, PASCAL

_		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 2004/087194 A (DEVELOGEN AKTIENGESELLSCHAFT FUER ENTWICKLUNGSBIOLOGISCHE FORSCHUNG; 0) 14 October 2004 (2004-10-14) the whole document	1-41
P, X	CRAS-MÉNEUR C ET AL: "An expression profile of human pancreatic islet mRNAs by Serial Analysis of Gene Expression (SAGE)." DIABETOLOGIA. FEB 2004, vol. 47, no. 2, February 2004 (2004-02), pages 284-299, XP002330420 ISSN: 0012-186X the whole document	1-41

χ Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 3 June 2005	Date of mailing of the international search report 2:5. 08. 2005
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authorized officer Fayos, C

MERNATIONAL SEARCH REPORT

	·	PCT/EP2004/013175
(Continua	ition) DOCUMENTS CONSIDERED TO BE RELEVANT	District No.
ategory °	the first and appropriate of the relevant passages	Relevant to claim No.
	DATABASE GENBANK 'Online! 10 April 2005 (2005-04-10), XP002330263 retrieved from GENBANK Database accession no. NM_026522 abstract	1-41
•	OSHIMA KENJI ET AL: "Secretion of a peripheral membrane protein, MFG-E8, as a complex with membrane vesicles. A POSSIBLE ROLE IN MEMBRANE SECRETION" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 269, no. 4, February 2002 (2002-02), pages 1209-1218, XP002233407 ISSN: 0014-2956 cited in the application abstract page 1210, column 1, paragraph 3 - column	27,41
Y	2, paragraph 1 the whole document	1-41
' X Y	US 5 279 966 A (JESSELL ET AL) 18 January 1994 (1994-01-18) the whole document	1-21, 25-33 1-41
Υ Χ	US 2002/144296 A1 (WHEELER MATTHEW B ET AL) 3 October 2002 (2002-10-03) NM_005928 page 10, paragraph 90	25-27,41
X Y	EP 1 149 844 A (RIKEN) 31 October 2001 (2001-10-31) claims 1-10	1-21, 25-33 1-41
Y	KAWAMURA K ET AL: "A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells." DEVELOPMENT (CAMBRIDGE, ENGLAND) JAN 1999, vol. 126, no. 2, January 1999 (1999-01), pages 211-219, XP002330421 ISSN: 0950-1991 cited in the application the whole document	1-41

riemational application No. PCT/EP2004/013175

TILC . STARTE LE

INTERNATIONAL SEARCH REPORT

Observations where certain claims were for	und unsearchable (Continuation of item 2 of first sheet)
	respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to	·
Claims Nos.: because they relate to parts of the International Apparant extent that no meaningful International Search of the Interna	plication that do not comply with the prescribed requirements to such carried out, specifically:
	rafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is	lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inven	
see additional sheet	
As all required additional search fees were timely searchable claims.	y paid by the applicant, this International Search Report covers all
2. As all searchable claims could be searched with of any additional fee.	nout effort justifying an additional fee, this Authority did not invite payment
As only some of the required additional search covers only those claims for which fees were particular.	fees were timely paid by the applicant, this International Search Report aid, specifically claims Nos.:
4. No required additional search fees were timely restricted to the invention first mentioned in the 1-41 (partially)	paid by the applicant. Consequently, this International Search Report is eclaims; it is covered by claims Nos.:
Remark on Protest	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

claims: 1-41 (partially)

A pharmaceutical composition comprising SF1, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF1.

2. claims: 1-41 (partially)

A pharmaceutical composition comprising SF2, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF2.

claims: 1-41(partially)

A pharmaceutical composition comprising SF3, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF3.

4. claims: 1-41 (partially)

A pharmaceutical composition comprising SF4, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF4.

5. claims: 1-41 (partially)

A pharmaceutical composition comprising SF5, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF5.

6. claims: 1-41 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising SF6, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF6.

7. claims: 1-41(partially)

A pharmaceutical composition comprising SF7, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF7.

8. claims: 1-41 (partially)

A pharmaceutical composition comprising SF8, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions, its use in identification / screening methods, a non human transgenic animal or recombinant host cell exhibiting a modified expression of SF8.

9. claims: 1-24 (partially)

A pharmaceutical composition comprising an effector / modulator of any of SF1-SF8, its use for the treatment of pancreatic diseases, obesity, metabolic syndrome and / or other metabolic diseases or dysfunctions.

ERNATIONAL SEARCH REPORT

Information on patent family members

In ational Application No
PCT/EP2004/013175

Patent document cited in search report		Publication date	Patent family . member(s)		Publication date	
WO 2004087194	Α	14-10-2004	WO	2004087194	A2	14-10-2004
US .5279966	Α	18-01-1994	AU	713198	B2	25-11-1999
			AU	1269897	Α	15-05-1997
			ΑU	677185	B2	17-04-1997
			ΑU	3945593	Α	08-11-1993
			CA	2133443	A1	14-10-1993
			ΕP	0670895	A1	13-09-1995
			JP	7508402	T	21-09-1995
			WO	9320196	Al	14-10-1993
			US	5750502	Α	12-05-1998
			ZA	9302362	A	15-06-1994
US 2002144296	A1	03-10-2002	บร	2004064841	A1	01-04-2004
•			AU	8494801		25-02-2002
			WO	0214473	A2	21-02-2002
EP 1149844	Α	31-10-2001	JP	2001292778	 . А	23-10-2001
•			CA		A1 .	11-10-2001
			EP	1149844		31-10-2001
			ÜS		A1	19-06-2003